The Tokyo-based biopharmaceutical company is accelerating its pipeline by innovating at the intersection of biology, modality, and disease.
Putting innovation—and patients—in focus: A conversation with Astellas Pharma CEO Naoki Okamura
calendar_today
August 15, 2026
domain
mckinsey-and-company